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Epidermal growth factor receptor tyrosine kinase inhibi-
tors (EGFR-TKIs), such as gefitinib and erlotinib, have
achieved high clinical response rates in patients with
non-small cell lung cancers (NSCLCs), which possess
somatic mutations in the tyrosine kinase domain of the
epidermal growth factor receptor (EGFR) gene. However,
over time (median of 6-12 months), most tumors are
known to develop acquired resistance to EGFR TKIs.
Currently, there have been no effective treatment options
against NSCLC patients with the secondary T790M resis-
tance mutation, which occurs in 50% of patients with
acquired resistance to EGFR-TKIs. Here we identified
two novel HLA-A2-restricted T cell epitopes derived
from the T790M resistance mutation of EGFR, T790M-5
(MQLMPFGCLL) and T790M-7 (LIMQLMPFGCL), as a
potential target for immunotherapy against EGFR-TKI-
resistant patients. When peripheral blood cells were
repeatedly stimulated in vitro with these two peptides
and assessed by antigen-specific IFN-g secretion, T cell
lines specific to T790M-5 and T790M-7 could be estab-
lished in 5 of 6 (83%) and 3 of 6 (50%) healthy donors,
respectively. Additionally, the T790M-5- and T790M-7-
specific CTLs displayed an MHC class I-restricted reac-
tivity against NSCLC cell lines expressing both HLA-A2
and the T790M mutation. More interestingly, antigen-
specific T cell responses to these epitopes were more fre-
quently observed in EGFR-TKI-sensitive patients (3 of 6,
50%) than in EGFR-TKI-resistant patients (2 of 11, 18%),
suggesting the possibility that immune responses to the
T790M-derived neo-antigens might prevent acquisition
of EGFR-TKI resistance in NSCLC patients by eliminat-
ing cancer cells with the T790M mutation. Given high
immunogenicity in human T cells, these epitopes could
provide a novel immunotherapeutic approach against
NSCLC patients with the T790M mutation. Since T cell
repertoires with high avidities to the “neo-antigens”
derived from mutated amino acid sequences are expected
to be available due to lack of central and/or peripheral
T cell tolerance, the identified T790M-derived T cell
epitopes might be a highly attractive target for immu-
notherapeutic manipulation.
Authors’ details
1Department of Immunology and Immunotherapy, Kurume University School
of Medicine, Kurume, Japan. 2Cancer Vaccine Center, Kurume University,
Kurume, Japan. 3Department of Internal Medicine, Kurume University School
of Medicine, Kurume, Japan.
Published: 7 November 2013
doi:10.1186/2051-1426-1-S1-P235
Cite this article as: Sasada et al.: EGFR T790M mutation as a novel
target for immunotherapy against EGFR-TKI-resistant non-small cell
lung cancer. Journal for ImmunoTherapy of Cancer 2013 1(Suppl 1):P235.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
1Department of Immunology and Immunotherapy, Kurume University School
of Medicine, Kurume, Japan
Full list of author information is available at the end of the article
Sasada et al. Journal for ImmunoTherapy of Cancer 2013, 1(Suppl 1):P235
http://www.immunotherapyofcancer.org/content/1/S1/P235
© 2013 Sasada et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
